IGKV2D-28

Across TCGA pan-cancer cohorts, IGKV2D-28 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated IGKV2D-28 data layer compared with 19 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher IGKV2D-28 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated IGKV2D-28 expression acts as an unfavorable survival marker.

LIHC, ACC, and SKCM are the cancer types where IGKV2D-28 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	OS	Median	All	0.128	0.783	.001	36	view →
ACC	OS	Median	All	0.214	0.802	.002	15	view →
SKCM	DFS	Median	All	0.198	0.728	.015	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

IGKV2D-28–LIHC (OS)

Open the LIHC breakdown →